We are developing a pipeline of novel cancer therapeutics targeting intracellular and cell-surface targets. Our etiology-centric approach allows us to start with and stay closer to the most relevant and translatable microbiology for patients and thereby accelerates the pace of our pancreatic cancer therapies.

Vitalgenics is currently in preparation of a clinical trial for a novel therapy for Pancreatic Cancer that has shown tremendous promise in all of our extensive testing.